Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive.

AbbVie is tracking for a new high that may be reached before the end of the year. Acquisitions fuel the growth outlook, cash flow and capital returns.

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (“FDA”) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer’s. However, there is no molecule or a combination of molecules that enhance cognitive functions. Thanks to innovative approaches by companies such as Annovis Bio Inc. (NYSE: ANVS) ( profile ), there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications. Broadly speaking, there is ample reason to be bullish on new treatments for a variety of significant diseases, including AD and obesity, as companies such as Eli Lilly (NYSE: LLY) , Pfizer Inc. (NYSE: PFE) , Novo Nordisk (NYSE: NVO) and AbbVie Inc. (NASDAQ: ABBV) are making investments and progress on historically…

EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END

AbbVie's strategic diversification and strong financial position make it possible to sustain growth despite the perceived “Humira cliff.”

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

When in doubt, zoom out; these three growth stocks have a history of strong performance that is likely to continue for the next 10 years

These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates

PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The SARS-CoV-2, literally affected the whole world in these past years and has increased a global search for therapies and treatments. A report from Transparency Market Research said that: “the emergence of new variants of coronavirus will boost COVID-19 therapeutics market growth. Demand for drugs that can effectively treat new strains of the virus is likely to be significantly high, as these new variants may be less susceptible to existing therapeutics. This is projected to boost the COVID-19 therapeutics market size, as pharmaceutical companies race to develop new drugs and treatments to address these new variants. Even after the pandemic is under control, there would still be a need for treatments and therapies to help those who have been affected by the virus, including those with long-term effects. This is anticipated to continue to drive COVID-19 therapeutics market demand. Additionally, emergence of new variants of the virus and the possibility of future outbreaks are anticipated to prompt governments and private organizations to be better prepared for future pandemics.” Active companies in the biotech industry this week include Sunshine Biopharma Inc. (NASDAQ: SBFM), Novavax, Inc. (NASDAQ: NVAX), REGENXBIO Inc. (NASDAQ: RGNX), BIONTECH SE (NASDAQ: BNTX), Abbvie (NYSE: ABBV).

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves targeted at specific brain regions and has shown promise in easing symptoms for patients with treatment-resistant bipolar disorder.1 Initially approved for major depressive disorder by the FDA, iTBS offers … Continue reading "Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment"

AbbVie had a solid quarter, accelerating growth and giving positive guidance that has analysts lifting their price targets and the stock advancing.

Merck stock is down more than 4% after lowering its 2024 earnings outlook, but if you look beyond the headline numbers, this could be a chance to buy the dip

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)--

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END

Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024

PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this serious, debilitating condition. Moreover, rising healthcare expenditure and presence of favorable reimbursement policies are also contributing to the market expansion. New drugs in development having novel mechanisms of actions for this condition are further expected to bring more growth opportunities for this market in the near future. The fibromyalgia treatment market involves prescription drugs and non-prescription remedies that provide relief from fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. This market includes drugs like antidepressants, pain relievers and anti-seizure medications as well as non-drug options like physical therapy, osteopathic manipulation, massage therapy and cognitive behavioral therapy which are aimed at managing fibromyalgia symptoms and improving overall health and quality of life for sufferers. A report from Coherent Market Insights projected that the fibromyalgia treatment market is estimated to be valued at USD 3.07 Billion in 2024 and is expected to reach USD 3.86 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031. Active biotech, pharma companies in the markets this week include: Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie (NYSE: ABBV), Axsome Therapeutics, Inc. (NASDAQ: AXSM).

The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season

ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors

Biotech is an exciting and promising area, and investors with some patience, the stomach for volatility, and a high risk tolerance can potentially benefit.  

Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out.

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often fatal form of cancer affecting the pancreas. With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts. A recent report from BioSpace projected that the pancreatic cancer market size which grew to USD 2.05 billion in 2022 is estimated to hit approximately USD 7.4 billion by 2032, with a CAGR of 13.7% for the period of 2023 – 2032. The report said: “This growth is driven by increasing instances of pancreatic cancer and higher investments in pancreatic oncology research. In recent years, the pancreatic cancer market has experienced steady growth, largely driven by the increasing prevalence of pancreatic cancer cases globally. As of 2020, pancreatic cancer ranks as the third most common cause of cancer-related deaths worldwide, with over 64,000 new cases diagnosed in the United States alone in 2023, resulting in over 50,000 deaths.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), Renovaro, Inc. (NASDAQ: RENB), Altamira Therapeutics Ltd. (NASDAQ: CYTO), Pfizer Inc. (NYSE: PFE), AbbVie (NYSE: ABBV).

Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions.